PRKCB promoter methylation has been associated with prostate cancer, being able to independently predict disease recurrence, and with non-small cell lung cancer, where the level of PRKCB promoter methylation was notably greater in tumour tissue in comparison to the surrounding tissue, making PRKCB a potential methylation biomarker for the diagnosis of that type of cancer [22, 23]. Here, PRKCB is linked to non-small cell lung carcinoma.